Wedbush Reiterates “Outperform” Rating for Neurocrine Biosciences (NASDAQ:NBIX)

Wedbush reiterated their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research report released on Tuesday morning,RTT News reports. Wedbush also issued estimates for Neurocrine Biosciences’ Q1 2026 earnings at $1.10 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.58 EPS and Q4 2026 earnings at $1.68 EPS.

A number of other equities research analysts have also issued reports on NBIX. Royal Bank of Canada increased their price target on Neurocrine Biosciences from $137.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday. Evercore ISI cut their target price on Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. Piper Sandler reissued an “overweight” rating and issued a $154.00 price target (down from $160.00) on shares of Neurocrine Biosciences in a report on Tuesday. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 20th. Finally, BMO Capital Markets boosted their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a “market perform” rating in a report on Tuesday. Three research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $162.00.

Neurocrine Biosciences Stock Down 3.4 %

NASDAQ NBIX opened at $117.52 on Tuesday. Neurocrine Biosciences has a 52 week low of $84.23 and a 52 week high of $157.98. The company has a market capitalization of $11.63 billion, a P/E ratio of 35.72, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. The stock’s 50-day moving average price is $106.18 and its 200-day moving average price is $121.81.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.62). The firm had revenue of $572.60 million for the quarter, compared to analysts’ expectations of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Neurocrine Biosciences’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.20 EPS. Research analysts anticipate that Neurocrine Biosciences will post 4.28 EPS for the current year.

Neurocrine Biosciences declared that its board has approved a stock repurchase program on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 2,274 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $118.37, for a total value of $269,173.38. Following the sale, the director now directly owns 519,074 shares in the company, valued at approximately $61,442,789.38. This represents a 0.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Julie Cooke sold 700 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total value of $82,796.00. Following the transaction, the insider now owns 18,831 shares of the company’s stock, valued at approximately $2,227,330.68. The trade was a 3.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,907 shares of company stock worth $4,935,982 over the last quarter. Insiders own 4.30% of the company’s stock.

Institutional Trading of Neurocrine Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in NBIX. Tidal Investments LLC grew its stake in Neurocrine Biosciences by 52.8% in the 3rd quarter. Tidal Investments LLC now owns 15,043 shares of the company’s stock worth $1,733,000 after acquiring an additional 5,197 shares in the last quarter. GAMMA Investing LLC grew its stake in Neurocrine Biosciences by 32.0% in the fourth quarter. GAMMA Investing LLC now owns 2,295 shares of the company’s stock worth $313,000 after purchasing an additional 557 shares in the last quarter. First Hawaiian Bank increased its holdings in Neurocrine Biosciences by 21.3% during the 4th quarter. First Hawaiian Bank now owns 12,243 shares of the company’s stock worth $1,671,000 after purchasing an additional 2,150 shares during the period. Pallas Capital Advisors LLC raised its position in Neurocrine Biosciences by 19.0% during the 4th quarter. Pallas Capital Advisors LLC now owns 7,673 shares of the company’s stock valued at $1,047,000 after purchasing an additional 1,225 shares in the last quarter. Finally, Tealwood Asset Management Inc. lifted its holdings in shares of Neurocrine Biosciences by 1.0% in the 4th quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock worth $1,626,000 after buying an additional 118 shares during the period. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.